Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration

C. V. Fontanilla, Z. Ma, X. Wei, J. Klotsche, L. Zhao, P. Wisniowski, R. C. Dodel, Martin Farlow, W. H. Oertel, Yansheng Du

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.

Original languageEnglish
Pages (from-to)135-141
Number of pages7
JournalNeuroscience
Volume188
DOIs
StatePublished - Aug 11 2011

Fingerprint

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson Disease
Dopamine
Apoptosis Inducing Factor
Propolis
Corpus Striatum
Caspase 1
Dopaminergic Neurons
Neuroprotective Agents
Nitric Oxide Synthase Type II
Substantia Nigra
Cytochromes c
Neurodegenerative Diseases
Mitochondria
caffeic acid phenethyl ester

Keywords

  • CAPE
  • Mitochondria
  • MPTP
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. / Fontanilla, C. V.; Ma, Z.; Wei, X.; Klotsche, J.; Zhao, L.; Wisniowski, P.; Dodel, R. C.; Farlow, Martin; Oertel, W. H.; Du, Yansheng.

In: Neuroscience, Vol. 188, 11.08.2011, p. 135-141.

Research output: Contribution to journalArticle

Fontanilla, C. V. ; Ma, Z. ; Wei, X. ; Klotsche, J. ; Zhao, L. ; Wisniowski, P. ; Dodel, R. C. ; Farlow, Martin ; Oertel, W. H. ; Du, Yansheng. / Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. In: Neuroscience. 2011 ; Vol. 188. pp. 135-141.
@article{36842f866d304ff2a8d7e5201658e8fe,
title = "Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration",
abstract = "Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.",
keywords = "CAPE, Mitochondria, MPTP, Parkinson's disease",
author = "Fontanilla, {C. V.} and Z. Ma and X. Wei and J. Klotsche and L. Zhao and P. Wisniowski and Dodel, {R. C.} and Martin Farlow and Oertel, {W. H.} and Yansheng Du",
year = "2011",
month = "8",
day = "11",
doi = "10.1016/j.neuroscience.2011.04.009",
language = "English",
volume = "188",
pages = "135--141",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration

AU - Fontanilla, C. V.

AU - Ma, Z.

AU - Wei, X.

AU - Klotsche, J.

AU - Zhao, L.

AU - Wisniowski, P.

AU - Dodel, R. C.

AU - Farlow, Martin

AU - Oertel, W. H.

AU - Du, Yansheng

PY - 2011/8/11

Y1 - 2011/8/11

N2 - Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.

AB - Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.

KW - CAPE

KW - Mitochondria

KW - MPTP

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=79958772058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958772058&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2011.04.009

DO - 10.1016/j.neuroscience.2011.04.009

M3 - Article

C2 - 21571045

AN - SCOPUS:79958772058

VL - 188

SP - 135

EP - 141

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -